Radiopharmaceuticals for palliation of painful osseous metastases

Annu Navani, Howard Smith, Scott M Fishman

Research output: Contribution to journalArticle

Abstract

Bone pain secondary to metastases may develop in more than half of patients with metastatic cancer. The treatment of metastatic osseous pain usually begins with oral analgesics following the WHO-ladder followed by external beam radiotherapy, ablative nerve blocks and implantable devices. Despite aggressive interventions, pain control seems challenging in this population. Treatment strategies including bisphosphonates, mitoxantrone and hormonal therapy have recently come into light. In some cases of osseous metastasis, radiopharmaceuticals may prove to be beneficial as an additional non-invasive therapy. This discussion will review different radiopharmaceutical agents available today including Strontium-89 chloride, Phosphorus-32 orthophosphate and Samarium-153 lexidronam and their clinical considerations.

Original languageEnglish (US)
Pages (from-to)25-36
Number of pages12
JournalJournal of Cancer Pain and Symptom Palliation
Volume1
Issue number2
DOIs
StatePublished - Dec 15 2005

Fingerprint

Radiopharmaceuticals
Neoplasm Metastasis
Pain
Mitoxantrone
Nerve Block
Diphosphonates
Therapeutics
Phosphorus
Analgesics
Radiotherapy
Phosphates
Light
Bone and Bones
Equipment and Supplies
Population
Neoplasms

Keywords

  • Bone
  • Metastases
  • Pain
  • Palliation
  • Radiopharmaceuticals

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology

Cite this

Radiopharmaceuticals for palliation of painful osseous metastases. / Navani, Annu; Smith, Howard; Fishman, Scott M.

In: Journal of Cancer Pain and Symptom Palliation, Vol. 1, No. 2, 15.12.2005, p. 25-36.

Research output: Contribution to journalArticle

@article{f6d66d00872543b3933c7bc4b5e3c6c0,
title = "Radiopharmaceuticals for palliation of painful osseous metastases",
abstract = "Bone pain secondary to metastases may develop in more than half of patients with metastatic cancer. The treatment of metastatic osseous pain usually begins with oral analgesics following the WHO-ladder followed by external beam radiotherapy, ablative nerve blocks and implantable devices. Despite aggressive interventions, pain control seems challenging in this population. Treatment strategies including bisphosphonates, mitoxantrone and hormonal therapy have recently come into light. In some cases of osseous metastasis, radiopharmaceuticals may prove to be beneficial as an additional non-invasive therapy. This discussion will review different radiopharmaceutical agents available today including Strontium-89 chloride, Phosphorus-32 orthophosphate and Samarium-153 lexidronam and their clinical considerations.",
keywords = "Bone, Metastases, Pain, Palliation, Radiopharmaceuticals",
author = "Annu Navani and Howard Smith and Fishman, {Scott M}",
year = "2005",
month = "12",
day = "15",
doi = "10.1300/J427v01n02_04",
language = "English (US)",
volume = "1",
pages = "25--36",
journal = "Journal of Cancer Pain and Symptom Palliation",
issn = "1543-7671",
publisher = "Haworth Press Inc.",
number = "2",

}

TY - JOUR

T1 - Radiopharmaceuticals for palliation of painful osseous metastases

AU - Navani, Annu

AU - Smith, Howard

AU - Fishman, Scott M

PY - 2005/12/15

Y1 - 2005/12/15

N2 - Bone pain secondary to metastases may develop in more than half of patients with metastatic cancer. The treatment of metastatic osseous pain usually begins with oral analgesics following the WHO-ladder followed by external beam radiotherapy, ablative nerve blocks and implantable devices. Despite aggressive interventions, pain control seems challenging in this population. Treatment strategies including bisphosphonates, mitoxantrone and hormonal therapy have recently come into light. In some cases of osseous metastasis, radiopharmaceuticals may prove to be beneficial as an additional non-invasive therapy. This discussion will review different radiopharmaceutical agents available today including Strontium-89 chloride, Phosphorus-32 orthophosphate and Samarium-153 lexidronam and their clinical considerations.

AB - Bone pain secondary to metastases may develop in more than half of patients with metastatic cancer. The treatment of metastatic osseous pain usually begins with oral analgesics following the WHO-ladder followed by external beam radiotherapy, ablative nerve blocks and implantable devices. Despite aggressive interventions, pain control seems challenging in this population. Treatment strategies including bisphosphonates, mitoxantrone and hormonal therapy have recently come into light. In some cases of osseous metastasis, radiopharmaceuticals may prove to be beneficial as an additional non-invasive therapy. This discussion will review different radiopharmaceutical agents available today including Strontium-89 chloride, Phosphorus-32 orthophosphate and Samarium-153 lexidronam and their clinical considerations.

KW - Bone

KW - Metastases

KW - Pain

KW - Palliation

KW - Radiopharmaceuticals

UR - http://www.scopus.com/inward/record.url?scp=33746890124&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746890124&partnerID=8YFLogxK

U2 - 10.1300/J427v01n02_04

DO - 10.1300/J427v01n02_04

M3 - Article

AN - SCOPUS:33746890124

VL - 1

SP - 25

EP - 36

JO - Journal of Cancer Pain and Symptom Palliation

JF - Journal of Cancer Pain and Symptom Palliation

SN - 1543-7671

IS - 2

ER -